For a patient with a boil and abscess, should I prescribe Bactrim (trimethoprim‑sulfamethoxazole) or Zyvox (linezolid)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Bactrim is the preferred first-line choice for a boil with abscess

For an outpatient with a boil and abscess, prescribe Bactrim (trimethoprim-sulfamethoxazole) 1-2 double-strength tablets twice daily for 5-10 days after incision and drainage. Zyvox (linezolid) is equally effective but significantly more expensive and should be reserved as an alternative when Bactrim cannot be used 1, 2.

Primary Treatment: Incision and Drainage

The cornerstone of treatment is incision and drainage (I&D), which may be sufficient alone for simple abscesses 1, 2. However, antibiotics are recommended when the abscess is associated with:

  • Severe or extensive disease involving multiple sites
  • Rapid progression with associated cellulitis
  • Signs of systemic illness (fever, elevated white count)
  • Comorbidities or immunosuppression
  • Extremes of age
  • Difficult-to-drain locations (face, hand, genitalia)
  • Lack of response to I&D alone 1, 2

Why Bactrim Over Zyvox

Both antibiotics have equivalent efficacy (A-II level evidence) for CA-MRSA skin and soft tissue infections 1, 2. The 2011 IDSA guidelines list them as equal options for empirical coverage of community-acquired MRSA in outpatients with purulent skin infections.

The critical difference is cost. The guidelines explicitly note that linezolid "is not superior to less expensive alternatives" 1. A 2012 study demonstrated average cost savings of $2,067 per patient when using TMP-SMX instead of linezolid or daptomycin, with comparable clinical outcomes 3.

Recent high-quality evidence from a 2016 randomized controlled trial showed TMP-SMX resulted in 80.5% clinical cure versus 73.6% for placebo in drained abscesses (P=0.005), confirming its effectiveness 4. A 2015 non-inferiority trial demonstrated TMP-SMX plus rifampin was non-inferior to linezolid for various MRSA infections 5.

Dosing Specifics

Adults: TMP-SMX 1-2 double-strength tablets (160/800 mg) twice daily 1, 6

Children: Trimethoprim 4-6 mg/kg/dose every 12 hours (not for infants <2 months) 1

Duration: 5-10 days, individualized based on clinical response 1, 2

When to Choose Zyvox Instead

Reserve linezolid (600 mg twice daily) for:

  • Documented TMP-SMX resistance on culture
  • Severe sulfa allergy (not just rash—anaphylaxis or Stevens-Johnson syndrome)
  • Pregnancy (third trimester) where TMP-SMX is category C/D 1
  • Renal insufficiency with hyperkalemia risk, as TMP-SMX can cause dangerous potassium elevation 7
  • Need for streptococcal coverage when you cannot add a beta-lactam, as linezolid covers both MRSA and streptococci 1, 2

Critical Caveats

TMP-SMX limitations:

  • Does not reliably cover beta-hemolytic streptococci 1. If concerned about strep (nonpurulent cellulitis component), add amoxicillin 500 mg three times daily 1
  • Monitor for hyperkalemia, especially in elderly patients on ACE inhibitors/ARBs or those with renal disease 7
  • Ensure adequate hydration to prevent crystalluria 7
  • Watch for rare but serious reactions: Stevens-Johnson syndrome, blood dyscrasias 7

Linezolid limitations:

  • Bacteriostatic (not bactericidal) 6, 8
  • Risk of thrombocytopenia and anemia with prolonged use
  • Serotonin syndrome risk with SSRIs
  • Significantly more expensive with no proven superiority 1

Culture Guidance

Obtain cultures from the abscess if prescribing antibiotics, especially if the patient has severe infection, systemic signs, or fails to respond to initial treatment 1, 2. This allows de-escalation if the organism is susceptible to narrower-spectrum agents or escalation if resistant.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.